The FDA has also granted tissue agnostic approval for the PD-1 inhibitor Pembrolizumab for any solid tumor with high microsatellite instability (MSI-H) due to the presumed increase in DNA mismatches and larger tumor antigen pool, though recent estimates suggest that this applies to fewer than 4% of cancer patients14–19. Here, PDCD1 is linked to neoplasm.